Pharmaceutical News

--Conference Call Scheduled for August 10, 2011, 8:30 a.m. U.S. EDT -- EXTON, Pa., Aug 09, 2011 (BUSINESS WIRE) --Adolor Corporation (NasdaqGM: ADLR) today announced that it will hold a conference call at 8:30 a.m. EDT on Wednesday, August 10, 2011, to discuss the results of its Phase 2 trials of ADL5945 in chronic opioid-induced constipation (OIC). To participate in the audio portion and have the opportunity to pose questions, dial 866-202-3109 for domestic callers or 617-213-8844 for international callers, and enter Conference ID # 62949696. Investors also can listen to the call live and view a slide presentation by log...

- ENTEREG Sales Growth Continues - - OIC Phase 2 Enrollment Complete; Results Expected in August - EXTON, Pa., Jul 27, 2011 (BUSINESS WIRE) --Adolor Corporation (NasdaqGM: ADLR) today reported net sales of ENTEREG(R) (alvimopan) of $8.2 million for the three months ended June 30, 2011, a 31% increase compared to net sales of $6.3 million for the three months ended June 30, 2010. The increase in net sales was driven primarily by an increase in the number of hospitals ordering ENTEREG and increased penetration within existing hospital customers, as well as the impact of pricing changes since the first quarter of 2010. Net sales of ENTEREG ...

-- Conference Call Scheduled for July 27, 2011, 8:30 a.m. U.S. EDT -- EXTON, Pa., Jul 21, 2011 (BUSINESS WIRE) --Adolor Corporation (NasdaqGM: ADLR) today announced that it will hold a conference call at 8:30 a.m. EDT on Wednesday, July 27, 2011, to discuss second quarter 2011 results. To participate in the audio portion and have the opportunity to pose questions, dial 866-383-8119 for domestic callers or 617-597-5344 for international callers, and enter Conference ID # 55315042. Investors also can listen to the call live by logging on to the Company's website at www.adolor.com and clicking on "Investor Insights," then "C...

-Management to Host Conference Call Wednesday, June 15, 2011 at 8:30 a.m.- EXTON, Pa., Jun 14, 2011 (BUSINESS WIRE) --Adolor Corporation (NasdaqGM: ADLR) today announced that it has entered into an agreement with GlaxoSmithKline (GSK) whereby Adolor will reacquire all rights to Adolor's FDA-approved product ENTEREG(R) (alvimopan). The transaction is expected to close in September 2011. Currently, ENTEREG is co-promoted by Adolor and GSK in the United States. "We are thrilled to have an agreement to acquire the rights to ENTEREG held by GSK," said Michael R. Dougherty, President and Chief Executive Officer. "We see continuing reve...

EXTON, Pa., Jun 06, 2011 (BUSINESS WIRE) --Adolor Corporation (NasdaqGM: ADLR) today announced that it has completed enrollment in its Phase 2 clinical evaluation of ADL5945 in chronic, non-cancer pain patients with opioid-induced constipation (OIC). Adolor is conducting two Phase 2 studies of ADL5945 in OIC patients in parallel. The first study is evaluating two doses of ADL5945 - 0.10 mg and 0.25 mg - given twice daily versus placebo over a 4-week, double-blind treatment period. The second study, of similar design, is evaluating 0.25 mg of ADL5945 given once daily versus placebo. The trials have enrolled 40 or more patients in ea...

EXTON, Pa., May 16, 2011 (BUSINESS WIRE) --Adolor Corporation (NasdaqGM: ADLR) today announced that ENTEREG(R) (alvimopan) will be the subject of presentations at the 2011 Annual Scientific Meeting of the American Society of Colon & Rectal Surgeons (ASCRS) on Monday and Tuesday, May 16-17, 2011. The presentations are scheduled from 9:00 a.m. to 4:00 p.m. EDT on Monday, May 16 and from 9:00 a.m. to 1:30 p.m. on May 17, 2011 in Exhibit Hall A, West Building at the Vancouver Convention Centre, Vancouver, Canada. A poster1 reporting the evaluation of ENTEREG use in clinical practice using a large in-patient database will be present...

- OIC Phase 2 Enrollment Progressing Well - EXTON, Pa., Apr 28, 2011 (BUSINESS WIRE) --Adolor Corporation (NasdaqGM: ADLR) today reported net sales of ENTEREG(R) (alvimopan) were $7.5 million for the three months ended March 31, 2011, a 42% increase compared to net sales of $5.3 million for the three months ended March 31, 2010. The increase in net sales was driven primarily by an increase in the number of hospitals ordering ENTEREG and increased penetration within existing hospital customers, as well as the impact of pricing changes since the first quarter of 2010. Net loss for the three months ended March 31, 2011 was $7.3 million, or ...

-- Conference Call Scheduled for April 28, 2011, 8:30 a.m. U.S. EDT -- EXTON, Pa., Apr 21, 2011 (BUSINESS WIRE) --Adolor Corporation (NasdaqGM: ADLR) today announced that it will hold a conference call at 8:30 a.m. EDT on Thursday, April 28, 2011, to discuss first quarter 2011 results. To participate in the audio portion and have the opportunity to pose questions, dial 866-831-6270 for domestic callers or 617-213-8858 for international callers, and enter Conference ID # 40429279. Investors also can listen to the call live by logging on to the Company's website at www.adolor.com and clicking on "Investor Insights," then "C...

EXTON, Pa., Apr 01, 2011 (BUSINESS WIRE) -- Adolor Corporation (NasdaqGM: ADLR) today announced that Michael R. Dougherty, President and Chief Executive Officer, will present at the Needham and Company, LLC, 10th Annual Healthcare Conference on Wednesday, April 6, 2011, at 3:20 P.M. Eastern Daylight Time. The conference is being held at the New York Palace Hotel, New York, NY. Adolor's presentation will be webcast live on the investor relations section of the Company's website and will be archived for one week following the broadcast. To access the webcast, log onto the Company's website at www.adolor.com and click on "Investor Insights," then "Webcast." Click on the link and follow the pr...

EXTON, Pa., Mar 02, 2011 (BUSINESS WIRE) --Adolor Corporation (NasdaqGM: ADLR) today announced that Michael R. Dougherty, President and Chief Executive Officer, will present at the Cowen and Company 31st Annual Health Care Conference on Monday, March 7, 2011, at 1:45 P.M. Eastern Time. The conference is being held at the Boston Marriott Copley Place, Boston, Massachusetts. Adolor's presentation will be webcast live on the investor relations section of the Company's website and will be archived for one week following the broadcast. To access the webcast, log onto the Company's website at www.adolor.com and click on "Investor...